Nii-Kono T - Search Results

1

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.

Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T; ROD21 Clinical Research Group. Koiwa F, et al. Among authors: nii kono t. Ther Apher Dial. 2005 Aug;9(4):336-9. doi: 10.1111/j.1744-9987.2005.00293.x. Ther Apher Dial. 2005. PMID: 16076378 Clinical Trial.

2

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M. Nakanishi S, et al. Kidney Int. 2005 Mar;67(3):1171-8. doi: 10.1111/j.1523-1755.2005.00184.x. Kidney Int. 2005. PMID: 15698459 Free article.

3

Role of fibroblast growth factor 23 in health and in chronic kidney disease.

Fukagawa M, Nii-Kono T, Kazama JJ. Fukagawa M, et al. Curr Opin Nephrol Hypertens. 2005 Jul;14(4):325-9. doi: 10.1097/01.mnh.0000172717.49476.80. Curr Opin Nephrol Hypertens. 2005. PMID: 15930999 Review.

4

Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism.

Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M. Nishi H, et al. Nephron Clin Pract. 2005;101(2):c94-9. doi: 10.1159/000086347. Epub 2005 Jun 14. Nephron Clin Pract. 2005. PMID: 15956805

5

Serum pro-hepcidin as an indicator of iron status in dialysis patients.

Tsuchihashi D, Abe T, Komaba H, Fujii H, Hamada Y, Nii-Kono T, Tanaka M, Fukagawa M. Tsuchihashi D, et al. Among authors: nii kono t. Ther Apher Dial. 2008 Jun;12(3):226-31. doi: 10.1111/j.1744-9987.2008.00578.x. Ther Apher Dial. 2008. PMID: 18503700

6

Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia.

Shiizaki K, Fukagawa M, Yuan Q, Hatamura I, Nii-Kono T, Saji F, Shigematsu T, Akizawa T. Shiizaki K, et al. Among authors: nii kono t. Am J Nephrol. 2008;28(1):59-66. doi: 10.1159/000109240. Epub 2007 Sep 28. Am J Nephrol. 2008. PMID: 17901691

7

No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism.

Nishi H, Nii-Kono T, Ikeda K, Fujimori A, Fukagawa M. Nishi H, et al. Among authors: nii kono t. Clin Nephrol. 2006 Feb;65(2):149-50. doi: 10.5414/cnp65149. Clin Nephrol. 2006. PMID: 16509469 No abstract available.

8

Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M. Iwasaki-Ishizuka Y, et al. Among authors: nii kono t. Nephrol Dial Transplant. 2005 Sep;20(9):1904-11. doi: 10.1093/ndt/gfh876. Epub 2005 Jun 28. Nephrol Dial Transplant. 2005. PMID: 15985520

9

Insufficiency of PTH action on bone in uremia.

Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M. Iwasaki Y, et al. Among authors: nii kono t. Kidney Int Suppl. 2006 Jul;(102):S34-6. doi: 10.1038/sj.ki.5001600. Kidney Int Suppl. 2006. PMID: 16810309 Free article. Review.

10

Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells.

Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, Yamato H, Kurokawa K, Fukagawa M. Nii-Kono T, et al. Kidney Int. 2007 Apr;71(8):738-43. doi: 10.1038/sj.ki.5002097. Epub 2007 Jan 31. Kidney Int. 2007. PMID: 17264878 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page